Strategies for the Cytosolic Delivery of Macromolecules: An Overview

Handbook of Pharmaceutical Biotechnology

Volumn , Issue , 2006, Pages 279-296

  Asokan, Aravind ^a   Cheung, Roland ^a   Cho, Moo J ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Endosome to cytosol transfer; Macromolecule cytosolic delivery strategy; Plasma membrane direct cytosolic delivery

Indexed keywords

EID: 84889816308     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470117118.ch3c     Document Type: Chapter

References (95)

1. Cho M J, Juliano R (1996). Macromolecular versus small-molecule therapeutics: Drug discovery, development and clinical considerations. Trends Biotechnol. 14:153-158.
2. Jain R K (1998). The next frontier of molecular medicine: delivery of thera peutics. Nat. Med. 4:655-657.
3. Brockman S, Murphy R (1993). Endosomal and lysosomal hydrolases. In T J Raub, K Audus (eds.), Biological Barriers to Protein Delivery: Plenum Press, New York, pp. 51-65.
4. Gray G D, Basu S, Wickstrom E (1997). Transformed and immortalized cellular uptake of oligodeoxynucleoside phosphorothioates, 3′-alkylamino oligonucleotides, 2′-Omethyl oligoribonucleotides, oligodeoxynucleoside methylphosphonates, and peptide nucleic acids. Biochem. Pharmacol. 53:1465-1476.
5. Juliano R L, Alahari S, Yoo H, et al. (1999). Antisense pharmacodynamics: Critical issues in the transport and delivery of antisense oligonucleotides. Pharmaceut. Res. 16:494-502.
6. Braasch D A, Corey D R (2002). Novel antisense and peptide nucleic acid strategies for controlling gene expression. Biochem. 41:4503-4510.
7. Conner S D, Schmid S L (2003). Regulated portals of entry into the cell. Nature. 422:37-44.
8. Cohen A W, Hnasko R, Schubert W, et al. (2004). Role of caveolae and caveolins in health and disease. Physiol. Rev. 84:1341-1379.
9. Saito G, Swanson J A, Lee K D (2003). Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv. Drug Del. Rev. 55:199-215.
10. Austin C D, Wen X, Gazzard L, et al. (2005). Oxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates, Proc. of the National Academy of Sciences of the United States of America. 102: 17987-17992.
11. Mastrobattista E, Koning G A, van Bloois L, et al. (2002). Functional characterization of an endosome-disruptive peptide and its application in cytosolic delivery of immunoliposome- entrapped proteins. J. Bioli. Chem. 277:27135-27143.
12. Li W, Nicol F, Szoka F C, Jr (2004). GALA: A designed synthetic pH-responsive amphipathic peptide with applications in drug and gene delivery. Adv. Drug Deli. Rev. 56:967-985.
13. Murthy N, Robichaud J R, Tirrell D A, et al. (1999). The design and synthesis of polymers for eukaryotic membrane disruption. J. Control. Rel. 61:137-143.
14. Stayton P S, El-Sayed M E, Murthy N, et al. (2005). "Smart" delivery systems for biomolecular therapeutics. Orthodn. Craniofacial Res. 8:219-225.
15. Midoux P, LeCam E, Coulaud D, et al. (2002). Histidine containing peptides and polypeptides as nucleic acid vectors. Somat Cell Molec. Genetics. 27:27-47.
16. Pack D W, Putnam D, Langer R (2000). Design of imidazole-containing endosomolytic biopolymers for gene delivery. Biotechnol. Bioengineer. 67:217-223.
17. Lee E S, Na K, Bae Y H (2005). Super pH-sensitive multifunctional polymeric micelle. Nano Letters. 5:325-329.
18. Boussif O, Lezoualc'h F, Zanta M A, et al. (1995). A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine, Proc. of the National Academy of Sciences of the United States of America. 92:7297-7301.
19. Kukowska-Latallo J F, Bielinska A U, Johnson J, et al. (1996). Efficient transfer of genetic material into mammalian cells using starburst poolyamidoamine dendrimers, Proc. of the National Academy of Sciences of the United States of America. 93:4897-4902.
20. Shi L, Yang L, Chen J, et al. (2004). Preparation and characterization of pH-sensitive hydrogel of chitosan/poly(acrylic acid) co-polymer. J. Biomat. Sci. Polymer Ed. 15:465-474.
21. Sonawane N D, Thiagarajah J R, Verkman A S (2002). Chloride concentration in endosomes measured using a ratioable fluorescent Cl- indicator: Evidence for chloride accumulation during acidification. J. Biolog. Chem. 277:5506-5513.
22. Yatvin M B, Kreutz W, Horwitz B A, et al. (1980). pH-sensitive liposomes: Possible clinical implications. Science. 210:1253-1255.
23. Connor J M, Yatvin B, Huang L (1984). pH-sensitive liposomes: Acid-induced liposome fusion, Proc. of the National Academy of Sciences of the United States of America. 81:1715-1718.
24. Simões S, Slepushkin V, Duzgunes N, et al. (2001). On the mechanisms of internalization and intracellular delivery mediated by pH-sensitive liposomes. Biochim. Biophys. Acta. 1515:23-37.
25. Wang C Y, Huang L (1987). pH-sensitive immunoliposomes mediate target-cell-specific delivery and controlled expression of a foreign gene in mouse, Proc. of the National Academy of Sciences of the United States of America. 84:7851-7855.
26. Collins D, Litzinger D C, Huang L (1990). Structural and functional comparisons of pH-sensitive liposomes composed of phosphatidylethanolamine and three different diacylsuccinylglycerols. Biochim. Biophys. Acta. 1025:234-242.
27. Semple S C, Klimuk S K, Harasym T O, et al. (2001). Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochim. Biophys. Acta. 1510:152-166.
28. Chen F J, Asokan A, Cho M J (2003). Cytosolic delivery of macromolecules: I. Synthesis and characterization of pH-sensitive acyloxyalkylimidazoles. Biochim. Biophys. Acta. 1611:140-150.
29. Asokan A, Cho M J (2003). Cytosolic delivery of macromolecules. II. Mechanistic studies with pH-sensitive morpholine lipids. Biochim. Biophys. Acta. 1611:151-160.
30. Asokan A, Cho M J (2004). Cytosolic delivery of macromolecules. 3. Synthesis and characterization of acid-sensitive bis-detergents. Bioconjug. Chem. 15:1166-1173.
31. Murthy, N, Thng Y X, Schuck S, et al. (2002). A novel strategy for encapsulation and release of proteins: Hydrogels and microgels with acid-labile acetal cross-linkers. J. Amer. Chem. Soc. 124:12398-12399.
32. Murthy N, Xu M, Schuck S, et al. (2003). A macromolecular delivery vehicle for protein-based vaccines: acid-degradable protein-loaded microgels, Proc. of the National Academy of Sciences of the United States of America. 100:4995-5000.
33. Wang C, Ge Q, Ting D, et al. (2004). Molecularly engineered poly(ortho ester) microspheres for enhanced delivery of DNA vaccines. Nat. Mat. 3:190-196.
34. Heffernan M J, Murthy N (2005). Polyketal nanoparticles: A new pH-sensitive biodegradable drug delivery vehicle. Bioconjug. Chem. 16:1340-1342.
35. Cordes E H, Bull H G (1974). Mechanism and catalysis for hydrolysis of acetals, acetals and orthoesters. Chem. Rev. 74:581-603.
36. Boomer J A, Thompson D H (1999). Synthesis of acid-labile diplasmenyl lipids for drug and gene delivery applications. Chem. Phys. Lipids. 99:145-153.
37. Guo X, Szoka F C, Jr (2001). Steric stabilization of fusogenic liposomes by a low-pH sensitive PEG-diortho ester-lipid conjugate. Bioconjug. Chem. 12:291-300.
38. Guo X, Szoka F C, Jr (2003). Chemical approaches to triggerable lipid vesicles for drug and gene delivery. Accounts of Chem. Res. 36:335-341.
39. Saito G, Amidon G L, Lee K D (2003). Enhanced cytosolic delivery of plasmid DNA by a sulfhydryl-activatable listeriolysin O/protamine conjugate utilizing cellular reducing potential. Gene Ther. 10:72-83.
40. Tang F, Hughes J A (1998). Introduction of a disulfide bond into a cationic lipid enhances transgene expression of plasmid DNA. Biochem. Biophys. Res. Communic. 242:141-145.
41. Byk G, Wetzer B, Frederic M, et al. (2000). Reduction-sensitive lipopolyamines as a novel nonviral gene delivery system for modulated release of DNA with improved transgene expression. J. Med. Chem. 43:4377-4387.
42. Chittimalla C, Zammut-ltaliano L, Zuber G, et al. (2005). Monomolecular DNA nanoparticles for intravenous delivery of genes. J. Amer. Chem. Soc. 127:11436-11441.
43. Pak C C, Ali S, Janoff A S, et al. (1998). Triggerable liposomal fusion by enzyme cleavage of a novel peptide-lipid conjugate. Biochim. Biophys. Acta. 1372:13-27.
44. Pak C C, Erukulla R K, Ahl P L, et al. (1999). Elastase activated liposomal delivery to nucleated cells. Biochim. Biophys. Acta. 1419:111-126.
45. Davis S C, Szoka F C, Jr (1998). Cholesterol phosphate derivatives: Synthesis and incorporation into a phosphatase and calcium-sensitive triggered release liposome. Bioconjug. Chem. 9:783-792.
46. Sarkar N R, Rosendahl T, Krueger A B, et al. (2005). "Uncorking" of liposomes by matrix metalloproteinase-9. Chem. Communicat. 999-1001.
47. Meers P (2001). Enzyme-activated targeting of liposomes. Adv. Drug Del. Rev. 53:265-272.
48. Anderson R G (1998). The caveolae membrane system. Ann. Rev. Biochem. 67: 199-225.
49. Nabi I R, Le P U (2003). Caveolae/raft-dependent endocytosis. J. Cell Biol. 161:673-677.
50. Pelkmans L, Helenius A (2002). Endocytosis via caveolae. Traffic. 3:311-320.
51. Sabharanjak S, Mayor S (2004). Folate receptor endocytosis and trafficking. Adv. Drug Del. Rev. 56:1099-1109.
52. Drummond D C, Hong K, Park J W, et al. (2000). Liposome targeting to tumors using vitamin and growth factor receptors. Vit. Hormones. 60:285-332.
53. Low P S, Antony A C (2004). Folate receptor-targeted drugs for cancer and inflammatory diseases. Adv. Drug Del. Rev. 56:1055-1058.
54. Leamon C P, Cooper S R, Hardee G E (2003). Folate-liposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: Evaluation in vitro and in vivo. Bioconjug. Chem. 14:738-747.
55. Derossi D, Calvet S, Trembleau A, et al. (1996). Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J. Biolog. Chem. 271: 18188-18193.
56. Vives E, Brodin P, Lebleu B (1997). A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biolog. Chem. 272:16010-16017.
57. Lindgren M, Hallbrink M, Prochiantz A, et al. (2000). Cell-penetrating peptides. Trends Pharmacol. Sci. 21:99-103.
58. Richard J P, Melikov K, Vives E, et al. (2003). Cell-penetrating peptides: A reevaluation of the mechanism of cellular uptake. J. Biolog. Chem. 278:585-590.
59. Ghibaudi E, Boscolo B, Inserra G, et al. (2004). The interaction of the cell-penetrating peptide penetratin with heparin, heparansulfates and phospholipid vesices investigated by ESR spectroscopy. J. Peptide Sci. 11:401-409.
60. Tyagi M, Rusnati M, Presta M, et al. (2001). Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans. J. Biolog. Chem. 276:3254-3261.
61. Foerg C, Ziegler U, Fernandez-Carneado J, et al. (2005). Decoding the entry of two novel cell-penetrating peptides in HeLa cells: lipid raft-mediated endocytosis and endosomal escape. Biochem. 44:72-81.
62. Jones S W, Christison R, Bundell K, et al. (2005). Characterisation of cell-penetrating peptide-mediated peptide delivery. British J. Pharmacol. 145:1093-1102.
63. Fischer R, Kohler K, Fotin-Mleczek M, et al. (2004). A stepwise dissection of the intracellular fate of cationic cell-penetrating peptides. J. Biolog. Chem. 279:12625-12635.
64. Potocky T B, Menon A K, Gellman S H (2003). Cytoplasmic and nuclear delivery of TAT-derived peptide and a beta-peptide after endocytic uptake into HeLa cells. J. Biolog. Chem. 278:50188-50194.
65. Wadia J S, Stan R V, Dowdy S F (2004). Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat. Med. 10:310-315.
66. Langel U (2005). Cell-penetrating peptides, mechanisms and applications. Curr. Pharmaceut. Des. 11:3595.
67. Astriab-Fisher A, Sergueev D, Fisher M, et al. (2002). Conjugates of antisense oligonucleotides with the Tat and antennapedia cell-penetrating peptides: Effects on cellular uptake, binding to target sequences, and biologic actions. Pharmaceut. Res. 19:744-754.
68. Koppelhus U, Awasthi S K, Zachar V, et al. (2002). Cell-dependent differential cellular uptake of PNA, peptides, and PNA-peptide conjugates. Antisense and Nucleic Acid Drug Devel. 12:51-63.
69. Moulton H M, Hase M C, Smith K M, et al. (2003). HIV Tat peptide enhances cellular delivery of antisense morpholino oligomers. Antisense Nucleic Acid Drug Dev. 13:31-43.
70. Oehlke J, Birth P, Klauschenz E, et al. (2002). Cellular uptake of antisense oligonucleotides after complexing or conjugation with cell-penetrating model peptides. Euro. J. Biochem. 269:4025-4032.
71. Xia H, Mao Q, Davidson, B L (2001). The HIV Tat Protein Transduction Domain Improves the Biodistribution of β-Glucuronidase Expressed from Recombinant Viral Vectors. Nat. Biotechnol. 19:640-644.
72. Bucci M, Gratton J P, Rudic R D, et al. (2000). In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nat. Med. 6:1362-1367.
73. May M J, D'Acquisto F, Madge L A, et al. (2000). Selective inhibition of NF-kB activation by a peptide that blocks the interaction of NEMO with the IkB kinase complex. Science. 289:1550-1554.
74. Kaufman C L, Williams M, Ryle L M, et al. (2003). Superparamagnetic iron oxide particles transactivator protein-fluorescein isothiocyanate particle labeling for in vivo magnetic resonance imaging detection of cell migration: uptake and durability. Transplantation. 76:1043-1046.
75. Torchilin V P, Levchenko T S, Rammohan R, et al. (2003). Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome-DNA complexes, Proc. of the National Academy of Sciences of the United States of America. 100:1972-1977.
76. Lee H J, Pardridge WM (2001). Pharmacokinetics and delivery of tat and tat-protein conjugates to tissues in vivo. Bioconjug. Chem. 12:995-999.
77. Pooga M, Soomets U, Hallbrink M, et al. (1998). Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. Nat. Biotechnol. 16:857-861.
78. Leifert J A, Harkins S, Whitton JL (2002). Full-length proteins attached to the HIV tat protein transduction domain are neither transduced between cells, nor exhibit enhanced immunogenicity. Gene Therapy. 9:1422-1428.
79. Ye D, Xu D, Singer A U, et al. (2002). Evaluation of strategies for the intracellular delivery of proteins. Pharmac. Res. 19:1302-1309.
80. Becker-Hapak M, McAllister S S, Dowdy S F (2001). TAT-mediated protein transduction into mammalian cells. Methods. 24:247-256.
81. Wadia J S, Stan R V, Dowdy S F (2004). Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat. Med. 10:310-315.
82. Ho A, Schwarze S R, Mermelstein S J, et al. (2001). Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo. Cancer Res. 61:474-477.
83. Futaki S (2002). Arginine-Rich Peptides: Potential for Intracellular Delivery of Macromolecules and the Mystery of the Translocation Mechanisms. Internat. J. Pharmac. 245:1-7.
84. Wender P A, Mitchell D J, Pattabiraman K, et al. (2000). The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: Peptoid molecular transporters, Proc. of the National Academy of Sciences of the United States of America. 97:13003-13008.
85. Morris M C, Vidal P, Chaloin L, et al. (1997). A new peptide vector for efficient delivery of oligonucleotides into mammalian cells. Nucleic Acids Res. 25:2730-2736.
86. Elliott G, O'Hare P (1997). Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell. 88:223-233.
87. Aints A, Guven H, Gahrton G, et al. (2001). Mapping of herpes simplex virus-1 VP22 functional domains for inter- and subcellular protein targeting. Gene Therapy. 8:1051-1056.
88. Hawiger J (1999). Noninvasive intracellular delivery of functional peptides and proteins. Curr. Opin. Chem. Biol. 3:89-94.
89. Jo D, Liu D, Yao S, et al. (2005). Intracellular protein therapy with SOCS3 inhibits inflammation and apoptosis. Nat. Med. 11:892-898.
90. Janout V, Staina I V, Bandyopadhyay P, Regen S L (2001). Evidence for an umbrella mechanism of bilayer transport. J. Amer. Chem. Soc. 123:9926-9927.
91. Janout V, Jing B, Regen S L (2005). Molecular Umbrella-Assisted Transport of an Oligonucleotide across Cholesterol-Rich Phospholipid Bilayers. J. Amer. Chem. Soc. 127:15862-15870.
92. Zaro J L, Shen W C (2003). Quantitative comparison of membrane transduction and endocytosis of oligopeptides. Biochem. Biophys. Res. Communicat. 307:241-247.
93. Lundberg M, Johansson M (2001). Is VP22 nuclear homing an artifact? Nat. Biotechnol. 19:713-714.
94. Loison F, Nizard P, Sourisseau T, et al. (2005). A ubiquitin-based assay for the cytosolic uptake of protein transduction domains. Molec. Ther. 11:205-214.
95. Kang S H, Cho M J, Kole R (1998). Up-regulation of luciferase gene expression with antisense oligonucleotides: Implications and applications in functional assay development. Biochem. 37:6235-6239.